February 23, 2017 / 8:02 AM / 5 months ago

BRIEF-Vicore Pharma resolves on directed share issues

1 Min Read

Feb 23 (Reuters) - Vicore Pharma Holding AB:

* Resolves on directed share issues and publish notice for an extraordinary shareholders' meeting

* Subscription price for share issues is set at 16 crowns per share

* Proceeds from share issues will primarily be used for clinical development of C21 through phase IB for idiopathic pulmonary fibrosis

* Says proceeds are also expected to suffice for financing of a clinical formulation for C21, interaction studies, a longer toxicity study and a conceptual clinical study in diabetes

* Total proceeds from share issues will amount to 56 million Swedish crowns ($6.2 million) before issue costs Source text for Eikon:

Further company coverage: ($1 = 8.9721 Swedish crowns) (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below